PMID- 37190135
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230519
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 8
DP  - 2023 Apr 8
TI  - Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and 
      Therapeutic Exploitation.
LID - 10.3390/cancers15082206 [doi]
LID - 2206
AB  - Evasion from immunity is a hallmark of cancer development. Dendritic cells (DCs) 
      are strategic immune cells shaping anti-tumor immune responses, but tumor cells 
      exploit DC versatility to subvert their functions. Unveiling the puzzling role of 
      DCs in the control of tumor development and mechanisms of tumor-induced DC 
      hijacking is critical to optimize current therapies and to design future 
      efficient immunotherapies for melanoma. Dendritic cells, crucially positioned at 
      the center of anti-tumor immunity, represent attractive targets to develop new 
      therapeutic approaches. Harnessing the potencies of each DC subset to trigger 
      appropriate immune responses while avoiding their subversion is a challenging yet 
      promising step to achieve tumor immune control. This review focuses on advances 
      regarding the diversity of DC subsets, their pathophysiology and impact on 
      clinical outcome in melanoma patients. We provide insights into the regulation 
      mechanisms of DCs by the tumor, and overview DC-based therapeutic developments 
      for melanoma. Further insights into DCs' diversity, features, networking, 
      regulation and shaping by the tumor microenvironment will allow designing novel 
      effective cancer therapies. The DCs deserve to be positioned in the current 
      melanoma immunotherapeutic landscape. Recent discoveries strongly motivate 
      exploitation of the exceptional potential of DCs to drive robust anti-tumor 
      immunity, offering promising tracks for clinical successes.
FAU - Sosa Cuevas, Eleonora
AU  - Sosa Cuevas E
AUID- ORCID: 0000-0002-2093-9707
AD  - EFS AuRA, R&D Laboratory, 38000 Grenoble, France.
AD  - Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Team: 
      Epigenetics, Immunity, Metabolism, Cell Signaling and Cancer, Universite Grenoble 
      Alpes, 38000 Grenoble, France.
FAU - Saas, Philippe
AU  - Saas P
AUID- ORCID: 0000-0002-8857-9939
AD  - EFS AuRA, R&D Laboratory, 38000 Grenoble, France.
AD  - Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Team: 
      Epigenetics, Immunity, Metabolism, Cell Signaling and Cancer, Universite Grenoble 
      Alpes, 38000 Grenoble, France.
FAU - Aspord, Caroline
AU  - Aspord C
AUID- ORCID: 0000-0002-4979-7044
AD  - EFS AuRA, R&D Laboratory, 38000 Grenoble, France.
AD  - Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Team: 
      Epigenetics, Immunity, Metabolism, Cell Signaling and Cancer, Universite Grenoble 
      Alpes, 38000 Grenoble, France.
LA  - eng
GR  - Grant 2020-2022/Etablissement Francais du Sang (EFS) AuRA/
GR  - Grant 2020-2022/Ligue contre le Cancer/
GR  - Grant 2020-2022/Societe Francaise de Dermatologie (SFD/
GR  - Grant 2020-2022/GEFLUC/
GR  - Grant 2021-2023/Fondation BMS/
GR  - Grant 2020-2022/Universite Grenoble Alpes (UGA)/
PT  - Journal Article
PT  - Review
DEP - 20230408
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10136655
OTO - NOTNLM
OT  - DC subsets
OT  - DC-based therapies
OT  - immune subversion
OT  - melanoma
OT  - prognostic factor
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript; or in the decision to publish the results.
EDAT- 2023/05/16 06:42
MHDA- 2023/05/16 06:43
PMCR- 2023/04/08
CRDT- 2023/05/16 01:13
PHST- 2023/02/21 00:00 [received]
PHST- 2023/03/31 00:00 [revised]
PHST- 2023/04/06 00:00 [accepted]
PHST- 2023/05/16 06:43 [medline]
PHST- 2023/05/16 06:42 [pubmed]
PHST- 2023/05/16 01:13 [entrez]
PHST- 2023/04/08 00:00 [pmc-release]
AID - cancers15082206 [pii]
AID - cancers-15-02206 [pii]
AID - 10.3390/cancers15082206 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Apr 8;15(8):2206. doi: 10.3390/cancers15082206.